Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 230 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Itraconazole Clear all
Completed Phase 1 Interventional Results available

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

NCT04537715
View directory record Official record
Conditions
All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma (ES), Synovial Sarcoma, Renal Medullary Carcinoma, Mesothelioma, Rhabdoid Tumor
Interventions
Tazemetostat, Itraconazole, Rifampin
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Encinitas, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers

NCT06543043
View directory record Official record
Conditions
Not Determined
Interventions
Phenytoin, Itraconazole, sonrotoclax
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants

NCT06722430
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Icalcaprant, Itraconazole (ITZ)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 4, 2026, 3:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants

NCT07242781
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986365, Itraconazole, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

NCT05720767
View directory record Official record
Conditions
Relapsed or Refractory Lymphoma
Interventions
HMPL-523, Itraconazole, Rifampin
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

NCT04606537
View directory record Official record
Conditions
Healthy, Drug Drug Interaction
Interventions
Itraconazole, Rifampin, KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin

NCT03174041
View directory record Official record
Conditions
Healthy Participants
Interventions
Midazolam, GDC-0853, Midazolam and GDC-0853, Rosuvastatin, Rosuvastatin and GDC-0853, Simvastatin, Simvastatin and GDC-0853, Itraconazole, GDC-0853 and itraconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

NCT06706869
View directory record Official record
Conditions
Healthy
Interventions
PF-07258669, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740

NCT05437094
View directory record Official record
Conditions
Clinical Pharmacology, Pharmacokinetics, Cardiovascular Diseases, Heart Failure
Interventions
CRD-740, Itraconazole
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

NCT06154447
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
12
States / cities
Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

NCT05518734
View directory record Official record
Conditions
Pain
Interventions
VX-708, Itraconazole, Midazolam, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 4, 2026, 3:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3154885 in Healthy Participants

NCT04014361
View directory record Official record
Conditions
Healthy
Interventions
LY3154885 - Capsule, Placebo - Capsule, Itraconazole, LY3154885 - Tablet
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

NCT02341482
View directory record Official record
Conditions
Healthy
Interventions
PF-04958242, Itraconazole
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Assessment of Mechanisms of Improved Wound Healing

NCT00673309
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion study, Insulin High Dose, oxandrolone, Propranolol, Growth Hormone, Insulin Low Dose, IGF-1/IGFBP-3, Itraconazole, Growth Hormone and Propranolol, Oxandrolone and Propranolol, Placebo or Control
Procedure · Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 90 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults.

NCT07575945
View directory record Official record
Conditions
Healthy Participant
Interventions
PF-08642534, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 4, 2026, 3:15 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.

NCT01752023
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
Cisplatin + Gemcitabine with SUBATM-itraconazole, Cisplatin + Gemcitabine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 4, 2026, 3:15 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)

NCT07661108
View directory record Official record
Conditions
Healthy
Interventions
MK-8527, Probenecid, Itraconazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

NCT02010970
View directory record Official record
Conditions
Healthy Volunteers, Pharmacologic Action
Interventions
Group 1 AZD3293, Group 2 AZD3293, Group 3 AZD3293, Group 1 Itraconazole, Group 2 Diltiazem, Group 3 Midazolam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 2 Interventional Results available

Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer

NCT01787331
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Itraconazole, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 4, 2026, 3:15 AM EDT
Terminated Phase 1 Interventional Results available

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

NCT02675452
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
Interventions
AMG 176, Azacitidine, Itraconazole
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants

NCT05338489
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib, Itraconazole, Rifampin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 4, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

NCT05860933
View directory record Official record
Conditions
Healthy
Interventions
LY3537982, Itraconazole, Carbamazepine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 4, 2026, 3:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole
Drug
Lead sponsor
Nuvalent Inc.
Industry
Eligibility
12 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Orange, California • Sacramento, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 4, 2026, 3:15 AM EDT
Not listed Early Phase 1 Interventional

Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy

NCT05076955
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
vancomycin-tobramycin-itraconazole
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 4, 2026, 3:15 AM EDT